From the Journals

Metabolic syndrome raises dementia risk in under-60s


 

FROM DIABETES CARE

Applicability ‘confusing’

In an interview, Yehuda Handelsman, MD, questioned the applicability of the study findings in the clinic. “Metabolic syndrome is a clinical manifestation of insulin resistance,” he said. “The more metabolic syndrome criteria a person has, the more insulin resistant that person will be. There is literature that is [suggesting] that insulin resistance is an important cause of dementia.”

Dr. Yehuda Handelsman, medical director and principal investigator at Metabolic Institute of America, Tarzana, Calif.

Dr. Yehuda Handelsman

The finding of a higher dementia risk before age 70, compared to afterward, makes the applicability “even more confusing,” he said. The results are even more muddled for U.S. physicians, who have moved away from the term metabolic syndrome in favor of cardiometabolic syndrome, said Dr. Handelsman, medical director and principal investigator at the Metabolic Institute of America and president of the Diabetes CardioRenal & Metabolism Institute, both in Tarzana, Calif.

Confusion also surrounds one of the components of metabolic syndrome: Waist circumference, per the harmonized definition the study used, and body mass index, which the more traditional definition uses.

Nonetheless, metabolic syndrome can be used as “kind of a risk calculator” for CVD, diabetes, and dementia, he said. One strength of the study, Dr. Handelsman said, is its size and scope, following 28 years of data. But a weakness was its observational design. “It doesn’t evaluate any true intervention to modify risk,” he said.

Dr. Machado-Fragua and coauthors have no disclosures.

Pages

Recommended Reading

Fatty liver disease drives rise in liver cancer deaths
Federal Practitioner
Pemvidutide promising for fatty liver disease
Federal Practitioner
Nordic walking bests other workouts on functional outcome in CVD
Federal Practitioner
Heart attack care not equal for women and people of color
Federal Practitioner
New European guidelines ‘drastically’ reduce statin eligibility
Federal Practitioner
An avocado a day doesn’t shrink belly fat, but helps with cholesterol
Federal Practitioner
Statins linked to lower diabetes risk after acute pancreatitis
Federal Practitioner
Rosuvastatin again linked with risks to kidneys
Federal Practitioner
Hypertension heightens risk for severe COVID-19, even in the fully vaxxed
Federal Practitioner
New update focuses on NAFLD in lean people
Federal Practitioner